Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] study

Introduction

double-blind, multicenter study

654 patients who required angiography

luminal narrowing of >= 20% in at least one coronary artery

Patients randomized to:

• pravastatin 40 mg or
• atorvastatin 80 mg daily

Baseline LDL cholesterol levels 150 mg/dL

Results:

• reduction of LDL cholesterol to
  • 110 mg/dL in pravastatin group
  • 79 mg/dL in atorvastatin group
• serum C-reactive protein baseline of 2.9 mg/dL, diminished
  • 5.2% in pravastatin group
  • 36% in atorvastatin group
• atheroma progression at 18 months, measured by intravascular ultrasound was less in the atorvastatin group compared to the pravastatin group
• lower LDL cholesterol & lower CRP levels independently associated less progression of atheroma volume

More general terms

• clinical trial

Additional terms

• PROVE-IT study